CELL INTELLIGENCE · 肿瘤细胞治疗研究

以双特异性抗体 XmAb 18968 靶向 CD38 治疗复发/难治性急性髓系白血病和 T 细胞急性淋巴细胞白血病患者

Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia

老年多发性骨髓瘤患者不断演变中的治疗格局：从四联方案到 T 细胞衔接器与 CAR-T

The Evolving Treatment Landscape for the Elderly Multiple Myeloma Patient: From Quad Regimens to T-Cell Engagers and CAR-T.

抗 CD38 单克隆抗体在年龄超过 65 岁且不适合干细胞移植的复发/难治性多发性骨髓瘤患者中的疗效：一项倾向评分匹配研究

Efficacy of Anti-CD38 Monoclonal Antibodies for Relapsed or Refractory Multiple Myeloma in Stem Cell Transplant-Ineligible Patients Aged over 65 Years

这些发现为不适合移植且年龄≥65 岁的 RRMM 患者以及适合接受 CAR-T 细胞或双特异性 T 细胞衔接器治疗等新方法候选者的抗 CD38 单克隆抗体最佳使用提供了见解。

OMIP-106：用于分析急性髓系白血病患者骨髓中检查点抑制网络的 30 色方案

OMIP-106: A 30-color panel for analysis of check-point inhibitory networks in the bone marrow of acute myeloid leukemia patients.

埃拉那单抗：首次批准

Elranatamab: First Approval.

不适合移植的新诊断多发性骨髓瘤 30 年生存改善

30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma.

儿童、青少年及年轻成人非霍奇金淋巴瘤的细胞与体液免疫治疗

Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma.